Background Despite the advances in the cure rate for acute myeloid leukemia (AML), a
considerable number of patients die from the disease due to the occurrence of multidrug …

The multidrug resistance (MDR) transporter-proteins P-glycoprotein (Pgp), multidrug
resistance protein (MRP) and lung resistance protein (LRP) have been associated with …

Resistance to chemotherapy is one of the major obstacles to effective treatment in acute
myeloid leukemia (AML). The most extensively studied protein involved in multidrug …

Immunocytochemical detection of the expression of the MRP gene and the MDR1 gene in
clinical specimens might be affected by several factors. Thus, we studied the impact of …

The multidrug resistance proteins (MRPs) MRP1, MRP2, MRP3, MRP5 and P-glycoprotein
(P-gp) act in concert with each other to give a net resultant pump function in acute myeloid …

Multidrug resistance (MDR) is believed to be responsible for poor response of patients
towards chemotherapy particularly patients with acute myeloid leukemia (AML) and acute …

Despite treatment with intensive chemotherapy, a considerable number of patients with
acute myeloid leukemia (AML) die from their disease due to the occurrence of resistance …

Therapeutic resistance is a major obstacle in the treatment of acute myeloid leukemia (AML).
Such resistance has been associated with rapid drug efflux mediated by the multidrug …

Overexpression of P-glycoprotein (Pgp) or MDR1 mRNA has been shown to be a negative
prognostic factor for clinical outcome in acute myeloid leukemia (AML). However, resistance …

Cytogenetic abnormalities are among the most important factors affecting the outcome of
patients with acute myeloid leukaemia (AML), but approximately 40–50% of AML cases …